Ariyan Ayati Firoozabadi

Ariyan Ayati Firoozabadi

Center for Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Tehrān, Iran
orcid
Medical Extern, School of Medicine, Shahid Beheshti Universi...

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
SKSajad Khodabandelu
Sajad Khodabandelu
SKSara Khaleghi
Sara Khaleghi
ANAnita Nourmohammadi
Anita Nourmohammadi
FJFarnaz Jafari
Farnaz Jafari
MRMohammad Rahmanian
Mohammad Rahmanian
Several earlier studies have shown that IBD (including its two subtypes, ulcerative colitis (UC) and Crohn’s disease (CD)) increases the risk of periodontal disease. This study aimed to evaluate the relevance among periodontitis and IBD subcategories. This study was conducted based on PRISMA guidelines. The Web of Science, PubMed, Google Scholar, and Scopus databases were searched up to February 2024 using pertinent keywords. Case series, review articles, and animal studies were excluded. The risk of bias in this research was evaluated through the Joanna Briggs Institute (JBI) criteria. The meta-analysis was conducted using R statistical software. A total of 9134 patients within 13 studies after the screening process were evaluated. Our study has shown that periodontitis is significantly more prevalent among IBD patients (UC and CD). According to prior meta-analyses, PD morbidity was found to be significantly high among CD patients (OR: 4.30; 95% CI: 3.72–4.98; I2 = 0%). Similarly, UC elevated PD risk (OR: 4.55; 95% CI: 3.76–5.50; I2 = 0%). The risk of periodontitis was not significantly different between CD and UC patients (OR: 0.96; 95% CI: 0.65–1.43; I2 = 34%). UC and CD patients were more likely to develop periodontitis, with low heterogeneity between studies, while the prevalence of periodontitis among UC and CD patients was not meaningfully different. The higher risk of periodontitis in patients with IBD indicates the necessity of screening for periodontitis. Considering the various oral manifestations and poor quality of life associated with IBD, it is important to be aware of the symptoms of periodontitis.

11 June 2025 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
AVAhmad Ghorbani Vanan
Ahmad Ghorbani Vanan
FGFarid Ghorbaninezhad
Farid Ghorbaninezhad
GNGolnaz Nikeghbali
Golnaz Nikeghbali
FMFateme Mohamadi
Fateme Mohamadi
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
ESElham Safarzadeh
Elham Safarzadeh
Long non-coding RNAs (lncRNAs) are a class of non-protein-coding RNAs that have over 200 nucleotides. Various studies have shown that aberrant expression of lncRNAs can lead to the development of different tumors. Furthermore, recent findings revealed that abnormal lncRNA expression can significantly influence cancer-related processes such as proliferation, migration, invasion, metastasis, and epithelial–mesenchymal transition. Colon cancer-associated transcript 2 (CCAT2), a type of lncRNA, was initially identified as an oncogene in colon cancer and subsequently identified as a prognostic biomarker in different cancers, including hepatocellular carcinoma, esophageal squamous cell carcinoma, ovarian cancer, lung cancer, breast cancer, and other tumors. Cumulative studies have revealed that the overexpression of CCAT2 is significantly correlated with tumor size, tumor node metastasis (TNM stage), tumor progression, and poor clinical outcomes. The significant role of CCAT2 in various gastrointestinal (GI) malignancies has drawn increased attention in recent years. In the present study, we reviewed recent literature concerning lncRNA CCAT2’s role in the development and progression of different GI cancers, including colorectal, gastric, hepatocellular, and oropharyngeal cancer, its interaction with cancer-related molecular mechanisms, and evaluate its potential as a diagnostic and prognostic biomarker in GI patients. In addition, this study shows that CCAT2 can be applied as a novel target for treatment strategies in gastrointestinal cancers.

18 December 2025 in PLOS ONE
Verified
Journal Article
Open access
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
IVIman Elahi Vahed
Iman Elahi Vahed
PLPouyan Lotfi
Pouyan Lotfi
AGAdel Geshani
Adel Geshani
AKAli Keshavarzian
Ali Keshavarzian
MRMohammad Rahmanian
Mohammad Rahmanian
Background: Non-alcoholic fatty liver disease (NAFLD) and hypothyroidism are both prevalent conditions with potential reciprocal influences. This study evaluates the link between NAFLD and hypothyroidism. Methods: A systematic search was performed using Scopus, PubMed, Web of Science, and Google Scholar. A random-effects meta-analysis assessed the bidirectional connection between hypothyroidism and NAFLD. Subgroup, meta-regression, and sensitivity analyses explored variability. R software (version 4.4.1) was employed for all analyses. Results: Data from 38,877,762 people were assessed, with 99% being female, limiting generalizability to male populations. Among the study population, females were significantly more numerous than males. Hypothyroidism increased the presence of NAFLD and nonalcoholic steatohepatitis (NASH) (OR = 1.96, 95% CI = 1.34–2.87; I2 = 89%). In subgroup analysis, the incidence of NAFLD/NASH was increased in both subclinical and unspecified hypothyroidism patients (OR = 1.59, 95% CI = 1.08–2.35; I2 = 91%, and OR = 1.96, 95% CI = 1.09–3.54; I2 = 79%, respectively). Conversely, overt hypothyroidism did not significantly increase the risk of NAFLD/NASH (OR = 4.27, 95% CI = 0.90–20.19; I2 = 89%). Additionally, NAFLD patients were more likely to develop hypothyroidism (OR = 1.85, 95% CI = 1.35–2.53; I2 = 100%). According to the subgroup analysis, NAFLD patients were more prone to develop subclinical hypothyroidism (OR = 1.83, 95% CI = 1.11–3.03; I2 = 87%). The increased presence of overt hypothyroidism wasn’t found to be significant in NAFLD patients (OR = 1.94, 95% CI = 0.73–5.18). Conclusion: This study suggests a reciprocal connection between hypothyroidism and NAFLD, underscoring the need for integrated management strategies and additional research into the underlying mechanisms. The predominance of female participants, combined with high heterogeneity, limits the applicability of findings to broader populations.

1 January 2025 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
IVIman Elahi Vahed
Iman Elahi Vahed
YRYasaman Rahimi
Yasaman Rahimi
SKShima Karbasi
Shima Karbasi
ASali safdari
ali safdari
MRMohammad Rahmanian
Mohammad Rahmanian
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a persistent hepatic condition linked with cardiovascular disorders and metabolic disturbances. Characterized by inflammation, fat accumulation, and fibrosis within the liver, MASLD can develop into liver cancer and cirrhosis. With a global prevalence of 32.4%, the condition parallels rising obesity rates. Orlistat inhibits lipase enzymes and, therefore, reduces dietary fat absorption, which may benefit MASLD patients. The present systematic review and meta-analysis were performed in accordance with PRISMA guidelines. Searches of PubMed, Scopus, Web of Science, and Embase up to January 2025 were performed using specific keywords and MeSH terms. Bias assessment and data extraction were conducted using Joanna Briggs Institute (JBI) tools independently by two researchers. Statistical analyses were performed with Stata version 14, calculating standardized mean differences, 95% confidence intervals (CI), and heterogeneity (by performing Cochran’s Q test and I² index). Moreover, metaregression, subgroup analyses, and sensitivity analyses were conducted. Eleven studies featuring 582 participants were included. Orlistat treatment induced a significant reduction in levels of alanine transaminase (ALT) (SMD = -26.23; 95% CI = -34.70 to -17.76) and aspartate aminotransferase (AST) (SMD = -19.62; 95% CI = -28.33 to -10.92). Furthermore, reductions in HOMA-IR, body mass index,cholesterol, insulin, and waist circumference were observed. The included studies exhibited low to moderate heterogeneity for most outcomes, indicating consistent results across trials. Orlistat significantly improved AST, ALT, and some other metabolic parameters in MASLD patients, suggest-ing its potential as an additional treatment option. However, the outcome must be interpreted cautiously, considering study heterogeneity. Further high-quality, multicenter research is necessary to confirm these results.

1 September 2025 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
NNNegarsadat Namazi
Negarsadat Namazi
ASAli Salmani
Ali Salmani
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
AMAmir Mehrvar
Amir Mehrvar
MPMohammad Poursalehian
Mohammad Poursalehian
SHSina Hajiaghajani
Sina Hajiaghajani

11 January 2026 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
MTMohsen Rafizade Tafti
Mohsen Rafizade Tafti
GNGolnaz Nikeghbali
Golnaz Nikeghbali
MVMani Velayati
Mani Velayati
MFMohammad Reza Fallahzadeh
Mohammad Reza Fallahzadeh
MNMohammad Hossein Nabian
Mohammad Hossein Nabian